[Treatment of rare cutaneous Tcell lymphoma and blastic plasmacytoid dendritic cell neoplasm]. / Therapie seltener kutaner TZell-Lymphome und der blastären plasmazytoiden dendritischen Zellneoplasie.
Hautarzt
; 68(9): 711-715, 2017 Sep.
Article
em De
| MEDLINE
| ID: mdl-28795194
ABSTRACT
Among the group of primary cutaneous lymphomas several subtypes have very low incidence rates. Based on the revision of the WHO classification for lymphoid neoplasms (2016), an overview of rare cutaneous Tcell lymphoma (CTCL) subtypes is given and therapeutic approaches are detailed. The prognosis of the different subtypes is highly variable underlining the importance of adequate stage and subtype adapted treatment. In cases of indolent subtypes topical treatment, e. g. topical corticosteroids or UV phototherapy are often sufficient. For aggressive variants, early discussion of more aggressive systemic treatment options is warranted.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Cutâneas
/
Linfoma Cutâneo de Células T
/
Doenças Raras
Idioma:
De
Ano de publicação:
2017
Tipo de documento:
Article